GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

Phase 3

Completed

Conditions: Asthma

Interventions: Biological: Mepolizumab
Drug: Placebo
Drug: SOC

First Posted Date: 2014-11-02

Last Posted Date: 2018-08-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 556

Registration Number: NCT02281318

Locations: 🇬🇧
GSK Investigational Site, Swansea, United Kingdom

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

Phase 1

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: Eltrombopag
Drug: Cyclosporine

First Posted Date: 2014-11-02

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 39

Registration Number: NCT02281370

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UMEC/VI DPI
Drug: Placebo DPI
Drug: Albuterol/salbutamol MDI

First Posted Date: 2014-10-27

Last Posted Date: 2018-08-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 198

Registration Number: NCT02275052

Locations: 🇺🇸
GSK Investigational Site, Union, South Carolina, United States

Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Congestion

Phase 4

Completed

Conditions: Nasal Congestion

Interventions: Device: Test strip
Device: Placebo strip
Other: Nasal spray

First Posted Date: 2014-10-27

Last Posted Date: 2017-08-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT02275364

Locations: 🇬🇧
Imanova Centre for Imaging Sciences, London, United Kingdom

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

Phase 2

Completed

Conditions: Infections, Streptococcal
Streptococcal Infections

Interventions: Biological: GBS Vaccine

First Posted Date: 2014-10-22

Last Posted Date: 2019-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1053

Registration Number: NCT02270944

Locations: 🇨🇿
GSK Investigational Site, Hradec Kralove, Czechia

Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study

Withdrawn

Conditions: Osteoarthritis

Interventions: Drug: Paracetamol 665 mg
Drug: Paracetamol 500 mg

First Posted Date: 2014-10-13

Last Posted Date: 2016-01-25

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02262702

To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK2256294
Drug: Placebo

First Posted Date: 2014-10-13

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT02262689

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UMEC/VI
Drug: Tiotropium
Drug: UMEC/VI matching placebo
Drug: Tiotropium matching placebo
Drug: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Drug: Indacaterol
Drug: Indacaterol matching placebo

First Posted Date: 2014-10-06

Last Posted Date: 2018-03-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 967

Registration Number: NCT02257385

Locations: 🇸🇰
GSK Investigational Site, Vrable, Slovakia

A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: UMEC DPI
Drug: Placebo DPI
Drug: ICS/LABA medication
Drug: Albuterol/salbutamol Metered Dose Inhaler (MDI)

First Posted Date: 2014-10-06

Last Posted Date: 2017-08-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 236

Registration Number: NCT02257372

Locations: 🇳🇱
GSK Investigational Site, Kloosterhaar, Netherlands

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers

Phase 1

Completed

Conditions: Embryo Transfer

Interventions: Drug: Epelsiban

First Posted Date: 2014-10-06

Last Posted Date: 2018-09-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT02257359

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy